A single testing of cardiac troponin I using a high-sensitivity assay can effectively rule out myocardial infarction (MI) without compromising safety, according to the HiSTORIC* study presented at the ESC 2019 Congress.
A newly developed clinical risk score can identify patients with type 2 diabetes (T2D) at greatest risk for hospitalization for heart failure (HHF) who would derive the most benefit from treatment with dapagliflozin, according to a study presented at ESC 2019.
Vegetarian and pescetarian diets are associated with a lower risk of ischaemic heart disease compared with a diet that include meat, according to the longitudinal EPIC*-Oxford study with 18 years of follow-up.
The incidence of cardiovascular disease (CVD)-related deaths is more common in low-income countries (LICs), while cancer-related deaths have increased in high-income countries (HICs) and some middle-income countries (MICs), according to new data from the PURE+ study presented at ESC 2019.
The Malaysian Endocrine and Metabolic Society (MEMS) and Malaysian Diabetes Educators Society (MDES) jointly launched the For Your Sweetheart campaign—a nationwide endeavour to increase public awareness and to educate Malaysians about diabetes-related heart disease.
People with sleep duration shorter than 6 hours/night have an increased risk of myocardial infarction (MI) than those who slept 6–9 hours/night, with additional data from Mendelian randomization supporting a causal link between sleep duration and MI, a new study has shown.
Beta-blockers could reduce mortality risk in patients with heart failure with reduced ejection fraction (HFrEF) and moderate or moderately-severe renal dysfunction without causing harm, according to the BB-META-HF* trial presented at ESC 2019.
Mortality is lower and outcomes are better among overweight patients following cardiac surgery, but when considering other preoperative variables, in-hospital and 1-year mortality do not appear to be independently influenced by body mass index (BMI), thus casting doubt on the “obesity paradox,” according to a study presented at the European Society of Cardiology Congress 2019 (ESC 2019).
The addition of ticagrelor to aspirin significantly reduced ischaemic events but led to an upsurge in major bleeding events relative to aspirin alone in individuals with stable coronary artery disease (CAD) and type 2 diabetes (T2D) without prior myocardial infarction (MI) or stroke. However, there was a favourable net clinical benefit in a subgroup with prior percutaneous coronary intervention (PCI), according to the results of the THEMIS* and THEMIS-PCI trials presented at the ESC Congress 2019.
Use of aspirin in the primary prevention of cardiovascular disease (CVD) in patients with no prior CVD history yields protection against the risks of acute myocardial infarction (AMI) and ischaemic stroke, but at the expense of an increase of similar magnitude in the incidence of major bleeding, according to the results of a recent meta-analysis presented at the European Society of Cardiology (ESC) Congress 2019 in Paris, France.
A comprehensive model of care delivered by nonphysician health workers (NPHWs), involving primary care physicians and families that was informed by local context, substantially improved blood pressure (BP) control and cardiovascular disease (CVD) risk, according to results of the HOPE 4 trial reported at the European Society of Cardiology (ESC) Congress 2019 and World Congress of Cardiology (WCC) 2019.